



ECS Botanics Holdings Ltd

An Australian medicinal cannabis cultivator and manufacturer

ASX : ECS
OCTOBER 2026

Nan-Maree Schoerie
CEO and Managing Director

Disclaimer

This presentation has been prepared by ECS Botanics Holdings Limited ("Company").

This presentation, dated 21 October 2026, should be read in conjunction with, and subject to, all information previously released to the market by Company. This presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in the Company.

In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. The information in this presentation is general only and does not constitute personal investment advice. Investors should assess their own personal financial circumstances, conduct their own investigations and consider seeking professional advice before making any investment decision. All securities involve risks which include (among others) the risk of adverse or unanticipated market, financial or political developments.

This presentation is for general information purposes only. Neither this presentation nor the information contained in it constitutes an offer, invitation, solicitation or

recommendation in relation to the purchase or sales of shares or other securities in any jurisdiction.

Certain statements in this presentation constitute forward looking statements which are based on information available to the Company as at the date of this presentation. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements.

While reasonable care has been taken in relation to the preparation of this presentation, none of the Company, its related entities, or their respective directors, officers, employees, contractors or agents accepts responsibility for any loss or damage resulting from the use of or reliance on this presentation by any person and, to the maximum extent permitted by law, all such loss and damage is expressly disclaimed.

No representation or warranty, express or implied, is made or given by or on behalf of the Company, its related entities, or their respective directors, officers, employees,

contractors or agents about the accuracy, completeness or fairness of any information or opinions contained in this presentation. No responsibility for any errors or omissions from this presentation arising out of negligence or otherwise are accepted.

Any opinions contained in this presentation reflect the Company's position at the date of this presentation based on information then known to the Company and are subject to change.

This presentation is not a prospectus, investment statement or disclosure document, or an offer of shares for subscription, or sale, in any jurisdiction. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The Company has not, and will not, register the offer of any shares under the *US Securities Act of 1933*. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.

All intellectual property, proprietary and other rights and interests in this presentation are owned by the Company.

Capital Structure

Market capitalisation

\$8.0m

As at 16 Oct 2026

Share price

\$0.005

As at 16 Oct 2026

Managing Director ownership

6.4%

As at 16 Oct 2026

Top 20 ownership

43%

As at 16 Oct 2026

Shares on issue

1.6b

As at 16 Oct 2026

Listed options (ECSO)

578m

As at 16 Oct 2026

Available Funding

\$4.5m

As at 30 Sep 2026

Cash/Drawn Debt

\$1.8m / \$2.5m

As at 30 Sep 2026



Corporate History


Australian Medicinal Cannabis Cultivator and Manufacturer

- ✓ ECS Botanics established in Tasmania in 2018 and listed on the ASX in 2019
- ✓ Acquired Murray Meds, located in NW Victoria, a GMP licensed facility in March 2021
- ✓ Low-cost production model able to produce quality medicinal cannabis products and also cater for budget brands
- ✓ 2024 – Certified Organic by The National Association for Sustainable Agriculture Australia (NASAA)
- ✓ Launched own brands in 2024, grown to >70% of revenue offsetting impact of lower cost imports
- ✓ Acquired exclusive licenses for VESIsorb[®] high bioavailability technology and Terphogz[®] branding



Accelerating Global Medical Cannabis Market

Forecast Growth: AUD \$65B in 2025 → AUD \$147B by 2030, a CAGR ~ 18%




Demand Driven by Unmet Needs

- Initial legalisation was driven by the incredible benefits of medical cannabis for intractable childhood epilepsy
- The global medicinal cannabis market is witnessing rapid expansion, driven by accelerating legalisation and innovation across therapeutic applications. Physicians continue to shift away from opioids towards cannabinoid therapies, particularly for chronic pain.
- With rising physician and consumer acceptance, the market is in the early stages of sustained growth as medicinal cannabis moves from early adopter to mainstream acceptance.



Medicinal cannabis dosage forms by gender

Approximate percentage of SAS-B approvals within each gender in 2025. Figures rounded from published descriptions.



TGA 2025 Reported Usage in Australia
Ratio of men to women patients is ~60:40

People, Process and Products

ECS has identified most successful genetics, built a strong bench and launched broad range of own brand products



GROW

Low-cost Australian cultivation

Outdoor and protected-cropping production provides scale across value and premium flower. Genetics selected for yield, quality and processing efficiency



MANUFACTURE

eu-GMP manufacturing

In-house processing and manufacturing supports finished-dose products and access to regulated export markets. Recent EU and UK changes requiring same site GMP plays to ECS strength



BRAND & DISTRIBUTE

Higher-value own-brand sales

OzSun, AVANI and other branded products capture more downstream value than traditional wholesale flower. ECS continues to take market share.

Major infrastructure investment is largely complete – growth can increasingly leverage the existing platform.

A growing portfolio across value, differentiated and premium products



OzSun

Value-led Australian-grown range of flower and pastilles

\$1.33m

Q1 flower sales

▲ **44.5% YoY**

Flower, oils and 2g all-in-one vapes



AVANI

Differentiated finished-dose products

+35.7%

YoY capsule sales

52.6% of AVANI capsule sales from VESISORB products



Portfolio expansion

Premium brands and new formats

- ✓ Terphogz premium portfolio
- ✓ OzSun vapes launched August
- ✓ AVANI AWA and other differentiated formats

ECS is an established Australian platform delivering results

Quarterly sales

\$5.49m

▲ 13.1% QoQ

Cash generation

5 quarters

Consecutive positive operating cash
flow

Quarterly B2C sales

\$3.91m

44.5% YoY sales growth

FY26 Revenue

\$21.4m

▲ 10% YoY

Market momentum

▲ **11.9% QoQ**


vs broader tracked panel -1.9%¹

FY26 EBITDA

+\$0.6m

Improved by \$5.8m YoY

Increasing productivity leveraging experienced team



FY26 outdoor
trimmed flower

3.1 tonnes

▲ 12% YoY

FY26 PCE
production

5.3 tonnes

▲ 43% YoY

Production cost per
gram

Reduced

▼ 33% - PCE
▼ 44% - outdoor

Operational
cultivation
infrastructure

26 PCEs

Protective cropping
enclosures

Four international pathways provide the next leg of commercial growth



UK – Curaleaf

- ✓ Six ECS-branded Australian-grown flower products
- ✓ Curaleaf provides local manufacturing and distribution
- ✓ Initial supply targeted November 2026



Germany – established market entry

- ✓ OzSun launched June 2026
- ✓ Initial shipment sold out within weeks
- ✓ Continuing to work with partners to expand Australian-grown supply



Poland - Koyi

- ✓ First flower registration approved
- ✓ ECS can now progress commercial supply
- ✓ First supply order expected Q2 FY27
- ✓ Second registration in progress




New Zealand – finished-dose exports

- ✓ 1,000-unit oil shipment completed
- ✓ Repeat order received
- ✓ Demonstrates export potential beyond flower

Unique IP

- AVANI Advanced capsules have a patented delivery system, VESIsorb®. Clinically proven in human trials to increase absorption of cannabidiol by 4x and 3x faster. ECS has a 10-year exclusive licence agreement for Australia and Europe

Summary of the pharmacokinetic (PK) parameters of two CBD formulations after administration of 25 mg CBD single oral dose.



Knaub et al., *Molecules* 24, 2967, 2019

"Natural products utilizing VESIsorb® sets the benchmark for delivering superior absorption and blood plasma levels."

Dr. Barry Ritz
Head of US Regulatory, Scientific & Medical Affairs
Nestlé Health Science U.S.

- Terphogz® are an award-winning Californian genetics producer. ECS has an 8-year exclusive licence agreement to produce and market under the Terphogz® brands.
- ECS launched Gelonoidz #20 in June 2026 as its first Australian-grown Terphogz product, with further cultivars forming part of the portfolio expansion strategy



Next proof points are commercial

Grow Australian brands

- Continue to take market share with Australian grown flower and recently introduced product formats such as All in One Vapes and Terphogz® flower
- Expand selected branded formats

Expand Exports

- Convert international pathways into recurring commercial revenue
- Build recurring export revenue across the UK, Germany, Poland and New Zealand
- Expand to more countries

Sustain and Grow Profits

- Positive FY26 EBITDA and five consecutive quarters of positive operating cash flow
- Low-cost operating model
- Higher utilisation, scale and yields provide operating leverage
- Leverage mix of production of flower, use of contract manufacturers and distribution to deliver growth without high levels of investment

Leverage IP

- Maximise penetration of IP
- Developing IP around bioburden reduction for non-irradiated flower
- Progressing to achieve certification for organic oils



AVANI

AUSTRALIAN GROWN,
NATURALLY

OzSun

AFFORDABLE MEDICINAL
CANNABIS FOR ALL
AUSTRALIAN PATIENTS

ECS BOTANICS — EST. 2018



ECS BOTANICS HOLDINGS LTD

Contact Us



Email us at
info@ecs-botanics.com

For investor and media enquiries:

Tim Dohrmann
tim@nwrcommunications.com.au